

JOSEPH DAMIEN SWEENEY

PRESENT ADDRESS: 145 Narragansett Ave
Riverside, RI 02915
Tel. (401)444-5152
Email: transfusionmed@gmail.com

UNIVERSITY EDUCATION:
1969 – 1976 University College, Galway, Ireland

UNDERGRADUATE DISTINCTIONS:
1969 Two University Scholarships Awarded
1970 Faculty of Medicine Scholarship
1972 Faculty of Medicine Scholarship
1974 Faculty of Medicine Scholarship

UNIVERSITY DEGREES:
1973 B.Sc - Major – Biochemistry (hons)
1976 M.B., B.Ch., B.A.O. - Medical Degree (hons-Obstetrics/Gynecology)

POST GRADUATE TRAINING: IRELAND

July 1976 - June 1977 Intern, International Missionary Training Hospital, Drogheda, Louth, Ireland. Teaching Hospital, Royal College of Surgeons, Ireland.

July 1977 - June 1978 Senior House Officer in Hematology, Federated Dublin, Voluntary Hospitals Meath Hospital, Dublin, Ireland. Teaching Hospital, Trinity College Medical School, Dublin, Ireland.

July 1978 - Dec. 1978 Senior House Officer in Internal Medicine, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland. Teaching Hospital, Royal College of Surgeons, Ireland.

Jan. 1979 - June 1979 Senior House Officer in Internal Medicine, International Training Hospital, Drogheda, Louth, Ireland. Teaching Hospital, Royal College of Surgeons, Ireland.

July 1979 - June 1980 Senior House Officer in Internal Medicine and the National Nephrology and Transplantation Center, Jervis Street Hospital, Dublin, Ireland. Teaching Hospital, Royal College of Surgeons, Ireland.

July 1980 - June 1981 Registrar in Hematology, Federated Dublin Voluntary Hospitals, Meath Hospital, Dublin, Ireland.

Honorary Registrar in Clinical Hematology, Clinical Hematology Unit and National Hemophilia Treatment Center, St. James Hospital, Dublin, Ireland. Teaching Hospitals, Trinity College Medical School, Dublin, Ireland.

POST GRADUATE EDUCATION: UNITED STATES

July 1981 - June 1982 Fellow in Hematology: Montefiore Hospital and Medical Center,
Bronx, New York 10467

Teaching Hospital, Albert Einstein College of Medicine, New York, NY

July 1982 - June 1983 Fellow in Blood Banking/Laboratory Hematology: Bronx Municipal
Hospital Center Pelham Parkway South and Eastchester Road, Bronx, New
York 10461

Teaching Hospital, Albert Einstein College of Medicine, New York, NY

June 1983 FLEX Examination - Passed (Weighted Av. Score: 87)

July 1983 - June 1984 Fellow in Medical Oncology
Roswell Park Memorial Institute
666 Elm Street
Buffalo, New York 14263
Teaching Hospital, State University of New York at Buffalo

PROFESSIONAL LICENSURE:

Medicine:	Ireland	S/9-669	(1976)
	New Jersey	#43287	(09/28/83)
	New York	#164778	(11/21/85)
	Virginia	#47247	(08/30/91)
	Rhode Island	#8484	(08/04/93) Active

BOARD CERTIFICATIONS:

I. EUROPE

1980 MRCPI - Membership, Royal College Physicians, Ireland (Internal Medicine)

1987 MRC Path-Membership, Royal College of Pathologists, England (Hematology/Blood Transfusion)

1997 Elected to Fellowship, Royal College of Pathologists (FRCPath)

1998 Elected to Fellowship, Faculty of Pathology, Royal College of Physicians, Ireland, (FFPath.RCPI).

II. UNITED STATES

1987 Diplomat, American Board of Internal Medicine (Internal Medicine)

- 1988 Certification of Special Qualification in Blood Banking, American Board of Pathology
- 1988 Diplomat, American Board of Internal Medicine, subspecialty Hematology
- 1992 Fellow, American College of Physicians (FACP)

ACADEMIC POSITIONS:

State University of NY at Buffalo: Assistant Professor of Medicine (1986- 1991)
 Eastern Virginia Medical School: Associate Professor of Pathology (1991-1994)
 Brown University Medical School: Associate Professor of Medicine (1994-1996)
 Brown University Medical School: Associate Professor of Medicine, Pathology and Laboratory Medicine (1996 - 2004)
 Brown University Medical School: Professor of Pathology, Laboratory Medicine and Medicine (2004-present)

WORK EXPERIENCE:

July, 1984 Staff Physician: Hematology-Oncology
 VA Medical Center
 3495 Bailey Avenue
 Buffalo, New York 14215
 Major Teaching Hospital of the State University of New York at Buffalo

December, 1984 Medical Co-Director
 Hemophilia Center of Western New York
 Erie County Medical Center
 Buffalo, New York 14215
 Teaching Hospital, State University of New York at Buffalo

August, 1986 Medical Director, Transfusion Service and Associate Chief
 Department of Laboratory Medicine
 Roswell Park Memorial Institute
 Buffalo, New York 14263
 Teaching Hospital, State University of New York at Buffalo

September, 1991 Medical Director, Mid-Atlantic Region American Red Cross, Blood Services
 611 West Brambleton Avenue
 Norfolk, VA 23510

January, 1992 Chief Medical Officer and Head of Research
 Mid-Atlantic Regional Blood Services
 American Red Cross
 611 West Brambleton Avenue
 Norfolk, VA 23510

January, 1994 Medical Director, Blood Bank
 The Miriam Hospital
 164 Summit Avenue

Providence, RI 02906

Medical Director, Blood Bank
Roger Williams Hospital
825 Chalkstone Avenue
Providence, RI 02908

- March, 1997 Director, Transfusion Medicine
Co-Director, Coagulation,
Lifespan Academic Medical Center
(Rhode Island Hospital and The Miriam Hospital)
Providence, RI
- December, 1999 Director, Transfusion Medicine and Coagulation
Lifespan Academic Medical Center
(Rhode Island Hospital and the Miriam Hospital)
Providence, RI
- September, 2004 Professor of Pathology, Laboratory Medicine and Medicine
Brown University Medical School
- November, 2006 Consultant in Transfusion Medicine
Women's and infants Hospital
Providence, RI
- August, 2008 Medical Director, School of Medical Technology,
Rhode Island Hospital

MEMBERSHIP OF COMMITTEES:

NATIONAL:

Member, Technical Committee, AABB (1999-2006).

HOSPITAL:

Chairman, Institutional Review Board, (IRB), Roswell Park Cancer Institute (1988-1991)
Chairman, Pathology Chair Search Committee, Roswell Park Cancer Institute (Ad Hoc) (1990-1991)
Chairman, Stem Cell Advisory Committee, Roswell Park Cancer Institute (1990-1991)
Member, Transfusion Committee, Roswell Park Cancer Institute (1986-1991)
Member, Transfusion Committee, Sentara Norfolk General Hospital (1991-1993)
Chairman, Transfusion Committee, The Miriam Hospital (1994-2000)
Chairman, Transfusion Committee, Roger Williams Medical Center (1994-present)
Member, Transfusion Committee, Rhode Island Hospital (1997-present)
Vice Chairman, Radiation Safety Committee, The Miriam Hospital (1994-2005)
Member, Credentials Committee, Roger Williams Medical Center (1995-1996)
Member, Research Advisory Committee, Lifespan Corporation (1995-1999)
Chairman, Data Safety Monitoring Board, Roger Williams Hospital (2002-present)
Chairman, Director of Microbiology search committee (ad hoc) 2002

UNIVERSITY:

Member, Radiation Safety Committee, Eastern Virginia Medical School (1993)

OTHER APPOINTMENTS AND AWARDS:

Inspector, Inspection and Accreditation Committee, *AABB* (1990)

Member Editorial Board, *Transfusion* (2005-present)

Scientific member, BEST committee (2007-present).

Elected as a member of Alpha-Omega-Alpha (AOA) by Faculty and Students at Brown University, (2014).

Milton Hamolsky Lifetime Achievement award from the Rhode Island Chapter of the American College of Physicians (2014)

MEMBERSHIP OF PROFESSIONAL SOCIETIES:

Member, International Society of Blood Transfusion

Member, International Society for Thrombosis and Hemostasis

Member, American Association of Blood Banks

Member, Society for the Advancement of Blood Management

BIBLIOGRAPHY PUBLICATIONS: PEER REVIEWED MANUSCRIPTS :

1. O'Neill S, **Sweeney JD**, Walker JF, O'Dwyer WF: Pneumothorax in the Ehlers-Danlos Syndrome. *Ir J Med Science*. 150:43-44, 1981.
2. **Sweeney JD**, Crosby R, McCann SR, Temperley IJ: Clinical Experience with Desamino-8-ARG Vasopressin (DDAVP) in Patients with Factors VIII Deficiency. *Ir J Med Science*. 150:236-239, 1981.
3. **Sweeney JD**, Spencer R, Donohoe JD, Carmody M, O'Dwyer WF: The Evaluation of Iron Status in Non-Dialysis Dependent Renal Failure. *Ir Med J*. 74:334-335, 1981.
4. **Sweeney JD**, Keane FB, Freyne PG, Temperley IJ, McCann SR: Accessory Splenic Tissue in a Patient with Relapsed Idiopathic Thrombocytopenic Purpura. *Clin Lab Hematol*. 4:309-312, 1982.
5. **Sweeney JD**, Firth RD, Strain S, Temperley IJ: von Willebrand's Disease in Ireland. *Ir Med J*. 75:245-247, 1982.
6. **Sweeney JD**, Daly H, Lawlor E, McCann SR, Temperley IJ: The Evaluation of the Patient with a Suspected Bleeding or Thrombotic Tendency. A Study of 290 Cases. *Ir Med J*. 76:449-453, 1983.
7. **Sweeney JD**, Wenz B: P Phenotype in an Ecuadorian Family. *Transfusion*. 24:25-28, 1984.
8. Bartlet J, **Sweeney JD**, Sadowsky J: Exodontia in Combined Factor V and Factor VIII Deficiency. *Am J Oral Maxillofacial Surgery*. 43:537-539, 1985.
9. **Sweeney JD**, Labuzetta JW, Fitzpatrick J: The Effect of the Platelet Count on the Aggregation Response and ATP Release in an Impedance Lumi-Aggregometer. *Am J Clin. Path*. 89:655-659,

1988.

10. **Sweeney JD**, Hassett JM: Intrasplenic Lymphoma Resembling Multiple Hematomas in a Hemophiliac. *Am J Hem.* 28:184-185, 1988.
11. **Sweeney JD**, Labuzetta JW, Hoernig L, Fitzpatrick J: Platelet Function and ABO Blood Group. *Am J Clin Path.* 91:79-81, 1989.
12. **Sweeney JD**, Ziegler P, Pruet C, Spaulding MB: Hyperzincuria and hypozincemia in patients treated with Cisplatinum. *Cancer.* 63:2093-2095, 1989.
13. **Sweeney JD**, Hoernig LA, Michnik AJ, Fitzpatrick JE: Whole Blood Aggregometry: Influence of Sample Collection and Delay in Performance on Test Result. *Am J Clin Path.* 92:676-679, 1989.
14. **Sweeney JD**, Hoernig LA, Fitzpatrick JE: Whole Blood Aggregation in von Willebrand's Disease. *Am J Hem.* 32, 190-193, 1989.
15. **Sweeney JD**, Labuzetta JW, Michielson C, Fitzpatrick JE: Comparison of Whole Blood Aggregometry Using Impedance and Particle Counter Methods. *Am J Clin Path.* 92:794-797, 1989.
16. **Sweeney JD**, Labuzetta JW, Bernstein ZP, Bielat KL, Fitzpatrick JE: Ristocetin Induced Platelet Aggregate Formation and Adherence to the Probe of an Impedance Aggregometer. *Am J Clin Path.* 93:548-551, 1990.
17. **Sweeney JD**, Hoernig LA, Behrens A, Novak E, Swank RT: von Willebrand Variant (Type II Buffalo) – thrombocytopenia after desmopressin but absence of *in vitro* Hypersensitivity to Ristocetin . *Am J Clin Path.* 93:522-525, 1990.
18. Jason J, Holman RC, Evatt BL and the Hemophilia-AIDS Collaborative Group (Member): Relationship of Partially Purified Factor Concentrates to Immune Tests and AIDS. *Am J Hematol.* 32:205-209, 1990.
19. **Sweeney JD**, Novak E, Reddington D, Swank RT: The RIII/SJ Inbred Mouse Strain as a Model for Von Willebrand's Disease. *Blood.* 76:2258-2265, 1990.
20. **Sweeney JD**, Killion K, Pruet CF, Spaulding MB: Von Willebrand Factor in Head and Neck Cancer. *Cancer.* 66:2387-2389, 1990.
21. **Sweeney JD**, Hoernig LA: Hemostatic Effects of Salsalate in Normal Subjects and Patients with Hemophilia A. *Thromb Res.* 61:23-27, 1991.
22. Bernstein ZP, Vaicus L, Friedman N, Goldrosen MH, Waternabe H, Rahman R, Ar buck SG, **Sweeney JD**, Vesper D, Henderson, ED, Zeffren J, Dennin RA, Levitt D, Foon KA: IL-2 LAK Therapy of non Hodgkin's Lymphoma and Hodgkin's Disease. *J Immunotherapy.* 10:141-146, 1991.

23. Bernstein ZL, Goldrosen MH, Vaicus L, Friedman N, Waternabe H, Rahman R, Park J, Arbuch S, **Sweeney JD**, Vesper D, Takita H, Zeffren J, Dennin RA, Foon KA: Interleukin-2/Lymphokine Activated Killer Therapy of Advanced Non-Small Cell Lung Cancer. *J Immunotherapy* 10:383-387, 1991.
24. Garcia G, Fitzpatrick JE, Hoernig LA, Steward CC, **Sweeney JD**: Effect of prestorage Leukodepletion on Platelet Glycoprotein IB and von Willebrand Factor. *Transfusion*. 32:148-151. 1992.
25. Anderson BW, Owczarczak B, **Sweeney JD**, Gessner T: Effects of *In vitro* Photodynamic Treatment of Endothelial Cells: Inhibition of Platelet Function. *Photochemistry and Photobiology*. 56:513-521, 1992.
26. **Sweeney JD**, Hoernig LA: Intraplatelet von Willebrand Factor and ABO Blood Group. *Thromb Res*. 68:393-398, 1992.
27. Foon KA, Goldrosen MH, Bernstein ZP, Vaicus L, Rahman R, Waternabe H, **Sweeney JD**, Park J, Vesper D, Russel D, Linna J, Farmer D, Lynch WH, Huben R, Walter PJ: Renal Cell Carcinoma Treated with Continuous Infusion Interleukin-2 with *ex vitro* Activated Killer Cells: Less Toxicity and Equivalent Response Rate to Bolus Interleukin-2. *J Immunotherapy*. 11:184-190, 1992.
28. **Sweeney JD**, Hoernig LA: Age dependent effect on the level of Factor IX. *Am J Clin Path*. 99:687-688, 1993.
29. Losonczy G, DiPirro J, **Sweeney J**, Brown G, Brentjens JH, Venuto R: The Effect of Pregnancy on the Response to the T_xA_z/PGH₂ Analogue U-46619 in Rabbits. *Am J Physiol*. 265:R772-R780, 1993.
30. **Sweeney JD**, Holme S, Moroff G. Storage of Apheresis Platelets after Gamma Radiation. *Transfusion*. 34:779-783, 1994.
31. **Sweeney JD**, Holme S, Heaton WAL, Campbell D, Bowen ML. Pseudothrombocytopenia in platelet-pheresis donors. *Transfusion*. 35:46-49, 1995.
32. **Sweeney JD**, Holme S, McCall L, Huett D, Storry J, Reid M. At(a-) Phenotype: Description of a family and reduced survival of At(a+) red cells in the propositi with anti At^a. *Transfusion*. 35:63-67, 1995.
33. **Sweeney JD**, Holme S, Heaton WAL, Stromberg RR. In vitro and in vivo effects of pre-storage filtration of apheresis platelets. *Transfusion*. 35:125-130, 1995.
34. **Sweeney JD**, Holme S, Heaton WAL, Nelson E. White cell reduced platelet concentrates prepared by in-line filtration of platelet rich plasma. *Transfusion*. 35:131-136, 1995.
35. Owens MR, **Sweeney JD**, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. *J Clin Apheresis*.

10:178-182,1995.

36. Busch MP, Collier A, Gernsheimer T et al (**Sweeney JD**, and the VATS group): The viral activation transfusion study (VATS): rationale objective and design overview. *Transfusion*. 36:854-859, 1996.
37. Holme S, Sawyer S, Heaton A, **Sweeney JD**. Studies on platelets exposed or stored at temperatures below 20°C or above 24°C. *Transfusion*. 37:5-11, 1997.
38. Arduino A, Holme S, **Sweeney JD**, Dottori S, Sciarroni A, Calvani N. Addition of L-carnitine to additive solution-suspended red cells stored at 4°C reduces in vitro hemolysis and improves in vivo viability. *Transfusion*. 37:166-174, 1997.
39. Holme S, **Sweeney JD**, Sawyer S, Elfath MD. P-selectin expression during collection, processing and storage of platelet concentrates: Relationship to loss of in vivo viability. *Transfusion*. 37:12-17, 1997.
40. Saba NF, **Sweeney JD**, Penn LC, Lawton JC, Yankee RL, Huang CH, Schanfield MS. Anti D in a Rhesus positive renal transplant patient. *Transfusion*. 37:321-324, 1997.
41. **Sweeney JD**, Blair AJ, King TC. Comparison of an activated partial thromboplastin time with a Russell Viper Venom time test in screening for FV Leiden (FVR506Q). *Am J Clin Pathol*. 108:74-77, 1997.
42. **Sweeney JD**, Blair AJ, Dupuis MP, King TC, Moulton AL. Aprotinin, cardiac surgery and Factor V Leiden. *Transfusion*. 37: 1173-1178, 1997.
43. **Sweeney JD**, Petrucci J, Yankee RL. Pooled platelet concentrates. Maybe not fancy, but fiscally sound and effective. *Transfusion and Apheresis Science*. 18: 575-583, 1997.
44. Kim MS, Kim HW, **Sweeney JD**, Greenburg AG. Decreased whole blood factor IX activity following hemodelution with hemodilution with hemoglobin A-zero in-vitro. *Artificial Cells, Blood Substitutes & Immobilization Biotechnology*. 25(3): 289-295, 1997.
45. **Sweeney JD**, Dumenco LL, Blair AJ, King TC. Hypercoagulable states and Factor V Leiden. *LabMedica International*. 15; 12-14, 1998.
46. Akhtar MS, Blair AJ, King TC, **Sweeney JD**. Whole blood screening test for Factor V Leiden (FVR506Q) using a Russell Viper Venom time based assay. *Am J Clin Pathol*. 109: 387-391; 1998.
47. **Sweeney JD**. Quality assurance and standards for red cells and platelets. *Vox Sang*. 74: 201-205, 1998.
48. Dumenco LL, Blair AJ, **Sweeney JD**. The results of diagnostic studies for Thrombophilia in a large group of patients with a personal or family history of thrombosis. *Am J Clin Pathol*. 110:

- 673-682, 1998.
49. Kluger NJ, Cummings FJ, Ready NE, **Sweeney JD**, Weitberg AB. Post transfusion non-cardiogenic pulmonary edema in a patient with chemotherapy-related hemolytic uremic syndrome. *Medicine & Health, Rhode Island*. 81(7): 235-236, 1998.
 50. **Sweeney JD**. Leukoreduction of the blood supply in Rhode Island. *Medicine & Health, Rhode Island*. 81, (12), 386-391, 1998.
 51. Moroff G, Holme S, AuBuchon JP, Heaton WA, **Sweeney JD**, Friedman LI. Viability and in vitro properties of gamma irradiated AS-1 red blood cell. *Transfusion*. 39: 128-134; 1999.
 52. Cyr M, Hume H, **Sweeney JD**, Blais C Jr, Gervais N, Adam A. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: A preliminary study. *Transfusion*. 39: 1084-1088, 1999.
 53. Lopez FF, **Sweeney JD**, Blair AJ, Sikov WM. Spontaneous venous thrombosis in a young patient with combined FV Leiden and lupus anticoagulant. *Am J Hem*. 62: 58-60, 1999.
 54. **Sweeney JD**, Kouttab N, Penn LC, McHugh K, Nelson EJ, Oblon DJ. A comparison of prestorage WBC-reduced whole-blood-derived platelets with bedside-filtered whole-blood-derived platelets in autologous progenitor cell transplant. *Transfusion*. 40: 794-800, 2000.
 55. **Sweeney JD**, Blair AJ, Cheves TM, Dottori S, Arduini, A. L-carnitine decreases glycolysis in liquid stored platelets. *Transfusion*. 40: 1313-1319, 2000.
 56. **Sweeney JD**. Platelet Transfusion: The case for dosing using platelet concentrates derived from whole blood donation. *Blood Therapies in Medicine*. 1: 34-40, 2001.
 57. **Sweeney JD**. Universal leukoreduction of cellular blood components in 2001? Yes. *Am J Clin Pathol*. 115 (5): 666-673, 2001.
 58. **Sweeney JD**, Arduini, A Role of L-Carnitine in Red Cell and Platelet Storage. *Trans Med Rev*. 18: 58-65, 2004.
 59. **Sweeney JD**, Kouttab NM, Holme SH, Kurtis JD, Cheves TA, Nelson EJ. Prestorage pooled whole blood derived leukoreduced platelets stored for seven days preserve acceptable quality and do not show evidence of a mixed lymphocyte reaction. *Transfusion*. 44: 1212-1219, 2004.
 60. **Sweeney JD**, Kouttab NM, Arduini A. L-Carnitine improves pH and decreases surface phosphatidylserine expression in extended stored apheresis platelets. *J Clin Apheresis*. 19: 98-102, 2004.
 61. Rabinowitz C, Movson JS, **Sweeney J**. Bilateral suburothelial renal sinus hemorrhage in a patient with severe coagulopathy due to acquired factor VIII antibody. *Clin Radiol Extra*. 59: 133-135, 2004.
 62. Barnett JM, Demel KC, Mega AE, Butera JN, **Sweeney JD**. Lack of Bleeding in Patients with Severe Factor VII Deficiency. *Am J Hematol*. 78: 134 -137, 2005.

63. **Sweeney JD**, Kurtis J, Starakovitz J. Residual risks of blood transfusion in Rhode Island. *Medicine & Health, Rhode Island.* 88: 224 - 231, 2005.
64. **Sweeney JD**, Kouttab NM, Holme SH, Kurtis JD, Cheves TA, Nelson EJ. Storage of Whole blood derived platelets in Plasma and additive solution. *Transfusion.* 46: 835- 840, 2006.
65. **Sweeney JD**. Standardization of the Red Cell Product. *Transfusion and Apheresis Science.* 34: 213-218, 2006.
66. Laga A, Cheves TA, **Sweeney JD**: Effect of Specimen Hemolysis on Coagulation Tests. *Am J Clin Pathol.* 126: 748-755, 2006.
67. **Sweeney JD**, Kouttab NM, Holme SH, Cheves TA, Nelson EJ. In vitro evaluation of Prestorage Pools consisting of Mixed A and O Platelets. *Transfusion.* 47: 1154-1161, 2007.
68. Laga A, Cheves TA, Maroto S, Coutts MT, **Sweeney JD**. The Suitability of Hemolyzed Specimens for Compatibility Testing Using Automated Technology. *Transfusion.* 48: 1713-1720, 2008.
69. **Sweeney JD** The Blood Bank Physician as a Hemostasis Consultant. *Transfusion and Apheresis Science.* 39: 145-150, 2008.
70. **Sweeney JD** Control of Blood Utilization. *Transfusion and Apheresis Science.* 39: 139-144, 2008.
71. Tormey C, **Sweeney JD**, Champion M, Pisciotto P, Snyder EL, Wu YY. Analysis of Transfusion Reactions Associated with Pre-Storage Pooled Platelet Components. *Transfusion.* 49:1242-1247 2009.
72. Spaete J, E, Rich J, **Sweeney JD**. Red Cell Exchange for babesiosis in Rhode Island. *J Clin Apheresis.* 24: 97-105, 2009.
73. **Sweeney JD**, Kouttab N, Kurtis JD. Stored Red Cell Supernatant facilitates thrombin generation. *Transfusion.* 49: 1569-1579, 2009.
74. Asad S, **Sweeney JD**, Mermel L : Transfusion Transmitted Babesiosis in Rhode Island. *Transfusion.* 49: 2564-2573, 2009.
75. Alhumaidan H, Cheves T, Holme S, **Sweeney JD**. Stability of clotting factors after 24 hour room temperature hold. *Transfusion.* 50: 1934-1942, 2010.
76. **Sweeney JD**. Venous Thromboembolic Disease. *Medicine & Health, Rhode Island.* 94: 98-104, 2011.
77. Tavares M, DiQuattro P, Nolette N, Conti G, **Sweeney JD**. Reduction in Plasma Transfusion After Enforcement of Transfusion Guidelines. *Transfusion.* 51: 754-761, 2011.

78. Heddle N M, Wu C , Vassallo R , Carey P, Arnold D , Lozano , M, Pavenski K, **Sweeney J**, Stanworth S, Liu Y, Traore A, Barty R, Tinmouth A. Challenges Adjudicating Bleeding Events in a Platelet Dose Study. *Transfusion.* 51: 2304-10, 2011.
79. Alhumaidan H, Cheves T, Holme S, **Sweeney JD**. Manufacture of Pooled Platelets in Additive Solution and a New Container after an overnight room temperature hold of Platelet Rich Plasma. *Am J Clin Pathol.* 136: 638-645, 2011.
80. Carino GP, Tsapenko AY, **Sweeney JD**. Central Line Placement in Patients With Coagulopathy With or Without Prophylactic Plasma. *J Crit Care.* 27: 529e9-529e13, 2012.
81. Alhumaidan H, **Sweeney JD**. Current status of additive solutions for platelets. *J Clin Apher.* 7: 93-98, 2012.
82. Chu LM, Lassaletta AD, Robich MP, Liu Y, Burgess T, Laham RJ, **Sweeney JD**, Shen T, Sellke FW: Effects of red wine and vodka on collateral-dependent perfusion and cardiovascular function in hypercholesterolemic swine. *Circulation.* 126 (suppl 1): S65-S72, 2012.
83. Meehan R, Tavares M, **Sweeney JD**. Clinical Experience with oral versus intravenous vitamin K for warfarin reversal. *Transfusion.* 53: 491-498, 2013
84. Alhumaidan H, Esteva C, Young C, Berardi V, Westerly B, **Sweeney JD**. Transfusion Transmitted Anaplasmosis from a leukoreduced Red cell. *Transfusion* 53:181-186. 2013
85. Alhumaidan H, Cheves T, Holme S, **Sweeney JD**. The effect of leukofiltration on plasma clotting factors. *Am J Clin Path.* 139: 110-116, 2013.
86. Layton J, Rubin L, **Sweeney JD**. Avoidance of Transfusion in Orthopedic Surgery. *Rhode Island Medical Journal.* 96: 23-25, 2013
87. Gross I, Shander A, **Sweeney JD**. Patient Blood Management and Outcome, Too Early or Not? Best Practice and Research: Clinical Anesthesiology. 27: 161-172, 2013
88. Tavares M, DiQuattro P, **Sweeney JD**. Reduction in Red Cell usage Associated with engagement of the ordering physician. *Transfusion.* 54: 2625-2630, 2014
89. Pinheiro L, Roberts L, **Sweeney JD**. Residual Plasma in Red Blood Cells and Transfusion Related Acute Lung Injury. *Transfusion.* 54: 2425-2430, 2014
90. Reagan JI, Inghram RR, Dalla S, Butera JN, **Sweeney JD**. Differences in the Clinical Course of Heparin Induced Thrombocytopenia Before and After the Availability of HIT IgG Class Testing. *Thromb Research.* 134: 90-92, 2014
91. **Sweeney JD**. Aggregates in Platelet Concentrates. *Vox Sanguinis.* 108, 96–125. 2015

92. Maslow A, Bert A, Singh A, **Sweeney JD**. Point of Care Hemoglobin/Hematocrit Testing: Comparison of Methodology and Technology. *J. Cardiothorac Vasc Anesthesia*. 30: 352–362 ,2016,
93. Fine AB, **Sweeney JD**, Nixon CP, Young CA, Knoll BM. Transfusion-transmitted anaplasmosis from a leukoreduced platelet pool .*Transfusion* 56: 699-704, 2016
94. Connell NT, Cheves TC, **Sweeney JD**. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura . *Transfusion*.56: 354-359, 2016
95. Nixon CP, **Sweeney JD**. Sulfamethoxazole induced thrombocytopenia masquerading as post transfusion purpura: a case report. . *Transfusion*. 55: 2738-2741, 2015
96. Nixon CP, **Sweeney JD**. Autoimmune Cytopenias. *Medicine & Health, Rhode Island*. (in press)
97. Nixon CP, Pricz E, Stevenson R, **Sweeney JD**. Acquired FXIII inhibitor associated with Mantle cell lymphoma. *Transfusion* (Submitted)

PEER REVIEWED LETTERS:

1. **Sweeney JD**, Wenz B. Combined Factor V and Factor VIII deficiency. *New England J Med*. 398: 656, 1983.
2. **Sweeney JD**, Orsini FR, Fitzpatrick JE. Alanine amino-transferase levels in blood donors. *Ann Int Med*. 107: 945, 1987.
3. **Sweeney JD**, Hoernig LA, Behrens A, Bloom M. Hand surgery in Glanzmann’s thrombasthenia. *Am J Hem*. 41: 140-141, 1992.
4. Garcia GI, **Sweeney JD**, White cell reduction in platelet concentrates. *Transfusion*. 32: 789, 1992.
5. **Sweeney JD**, Dupuis MP, Mega AJ. Hypotensive reactions in bedside filtered red cells, but not prestorage filtered red blood cells in patients taking ACE inhibitors. *Transfusion*. 38: 410-411; 1998.
6. Mylonakis T, Dickinson B, Feller A, **Sweeney JD**, Schiffman FJ, Rich J, Flanigan T. Combination antiretro-viral therapy including a protease inhibitor eliminating the transfusion requirements of HIV-infected individuals with anemia of chronic disease. *J Acq Imm Def Syn Hum Retrovir*. 19: 306-307, 1998.
7. **Sweeney JD**, Dupuis MP, Mega AJ. Hypotensive reactions during transfusion. Is bradykinin the culprit? (Response to letter). *Transfusion*. 39: 108-109; 1999.

8. Lopez F, Mega A, Schiffman F, **Sweeney JD**, Splenic infarction from factor V Leiden mutation. *Am J Hem.* 62: 62-63, 1999.
9. **Sweeney JD**, Dupuis MP, Testa G. Lack of macroscopic aggregates in pools of prestorage leukoreduced whole blood derived platelets. *Transfusion.* 40: 615-616, 2000.
10. **Sweeney JD**, Chai L. Universal Leukoreduction of Cellular Blood Components in 2001. *Amer J Clin Path.* 116: 778-779, 2001.
11. **Sweeney JD**, Holme S. Platelet Counts in Pools of Platelet Rich Plasma Derived Platelet Concentrates. *Vox Sang.* 89: 168, 2005.
12. Laga A, Kurtis J, **Sweeney JD**. Recurrent Transfusion Related Acute Lung Injury After Fresh Frozen Plasma in a Patient With Hereditary Factor V Deficiency. *Am J Hem.* 83 :680, 2008.

BOOKS/EDITOR: CHAPTERS

EDITOR:

Sweeney JD, Heaton, WAL (Eds.) *Clinical Benefit of Leukodepleted Blood Products.* RD Landes, Austin, Tx. 1995.

Sweeney JD, Rzik Y (Eds) . *A Handbook of Clinical Transfusion Medicine.* RD Landes, Austin, TX. 1999.

Sweeney JD, Lozano M (Eds). *Platelet Transfusion Therapy.* Bethesda MD: AABB, 2013:

GUEST EDITOR:

Sweeney JD. *Medicine and Health/Rhode Island. Blood Banking and Transfusion Medicine.* 81, (12), 1998.

Blajchman MA, Dzik S, Vamvakas EC, **Sweeney J**, Snyder EL. Clinical and molecular basis of transfusion-induced immunomodulation: Summary of the proceedings of a state-of-the-art conference. *Transfusion Medicine Reviews.* 15 (2): 108-135, 2001.

BOOK CHAPTERS:

1. **Sweeney JD**, Holme S, Heaton WAL. Leukodepletion and the Quality of Stored Red Cells and Platelets in Clinical Benefits of Leukodepleted Blood Products, (Eds) Sweeney, JD, Heaton WAL, RD Landes, Austin TX, 1995.
2. **Sweeney JD**, Holme S, Heaton WAL. Quality of platelet concentrates in *Transfusion Immunology and Medicine* (Ed) CJ Van Oss, Marcel Dekker, Inc, NY, 1995.
3. Carson JL, **Sweeney JD**. RBC filtration and allogeneic blood transfusion in: *Transfusion Medicine and Transfusion Alternatives.* RxJ Editors Medicales, Paris. 1st Edition, 2000.

4. **Sweeney JD**, Arduini A. The effect metabolic additives on platelet storage in Platelet Therapy: Current status and future challenges. E L Snyder and J Seghatchian (eds) , Elsevier Science, Amsterdam 1st Edition, 2000.
5. **Sweeney JD**. Blood component manufacture. Chapter 8. AABB Technical Manual, 14th and 15th Editions, 2002 and 2005.
6. **Sweeney JD**. Blood Administration. Chapter 22. AABB Technical Manual, 14th and 15th Editions, 2002 and 2005.
7. Connell NT, **Sweeney JD**. Does My Patient Have a Life- or Limb-Threatening Thrombocytopenia? In Hematology/Oncology Clinics of North America. Eds Schiffman FJ, Mega A . 26: 369-382, 2012.
8. **Sweeney JD**, Lozano M. Epidemiology of Platelet Transfusions. In Platelet Transfusion Therapy. Eds Sweeney JD, Lozano M. AABB Press, Bethesda MD. 2013. P 1-13
9. Lozano M, **Sweeney JD**. Alternatives to Platelet Transfusion. In Platelet Transfusion Therapy Eds. Sweeney JD, Lozano M. AABB Press, Bethesda, MD. 2013. p 567-589
10. **Sweeney JD**. Transfusion Therapy for Anemia. In Anemia: Pathophysiology, Diagnosis and Management. Eds Benz E, Berliner N, Schiffman FJ. Cambridge University press, Boston MA , 2015
11. **Sweeney JD**. Strategies for warfarin reversal in the hemorrhaging patient. In PBM case studies. Eds GrossI, Lieb M. AABB press, Bethesda, MD 2016

INVITED REVIEWS AND EDITORIALS:

Sweeney JD. Whole Blood Derived Platelets: A view from the USA. Transfusion Today, March, 2007.

Sweeney JD. Bursting the Bubble of the Bleeding Time: Advance/Laboratory, p30-34, August, 2007.

Tavares M, **Sweeney JD**. Non-Transfusion approaches to avoid Blood Transfusion. Advance/Laboratory, p30-34, October, 2008.

Sweeney JD. Platelet Additive Solutions: Is it time for North America to go with the Flow? Transfusion. 49: 199-200, 2009.

Shandler A, **Sweeney JD**. Overview of Treatment Regimens in Iron Chelation Therapy. US Hematology. 2: 59-62, 2009.

Guertin CA, **Sweeney JD**. Laboratory Evaluation of Thrombocytopenia. Advance/Laboratory, September, 2012

Nixon, CP, **Sweeney JD**. Discriminating different causes of transfusion associated pulmonary edema.

PUBLISHED ABSTRACTS:

1. **Sweeney JD**, Harris S, Wenz B. P Phenotype in a Ecuadorian family (Abstract and Poster). International Society of Hematology, Sept. 1984. Buenos Aires.
2. **Sweeney JD**, Killion K, Pruet C, Spaulding MB. Abnormalities of the Factor VIII complex in Squamous cell carcinoma of the head and neck. Blood. 66, 328a, 1985.
3. **Sweeney JD**, Belling L, Moriarty LA, Hoernig LA. A Study of the hemostatic and coagulation effects of salsalate in hemophilia. Blood. 66, 328a, 1985.
4. Hess H, **Sweeney JD**. The Effect of warfarin formulation on anticoagulant control. Blood. 66, 350a, 1985.
5. **Sweeney JD**, Bernstein ZP and Robson EB. Qualitative platelet abnormality in hemophilia A (Abstract and Poster). 38th Annual Meeting of the National Hemophilia Foundation, Washington, DC, September, 1985.
6. **Sweeney JD**, Bernstein ZP and Hassett JM. Histiocytic lymphoma resembling intrasplenic hematoma in a hemophiliac (Abstract and Poster). 38th Annual Meeting of the National Hemophilia Foundation, Washington, DC, September, 1985.
7. **Sweeney JD**, Hoernig LA and Labuzetta JW. Anticoagulant proteins in hemophilia A. Blood. 68, 341a, 1986.
8. Labuztta JW and **Sweeney JD**. Aggregation response and ATP release are related to platelet number and mean platelet volume in a whole blood aggregation system. Blood. 68, 336a, 1986.
9. **Sweeney JD**, Killion K, Hoernig LA, and Spaulding MB. Protein C in squamous cell carcinoma of the head and neck. Blood. 68, 342a, 1986.
10. **Sweeney JD**, Masferrer E, Ruth E, and Fitzpatrick JE: Absence of correlation between donor blood counts and plateletpheresis harvest yields using a discontinuous centrifugation system. Haemonetics 12th International Apheresis Symposium, April, 1987 (Oral Presentation).
11. **Sweeney JD**, Fitzpatrick L, Holmberg RP. Analysis of bleeding episodes and factor VIII usage in hemophilia A (Abstract and Poster). 39th Annual Meeting, National Hemophilia Foundation, Omaha, NE, October, 1987.
12. **Sweeney JD**, Labuzetta JW. Comparison of the changes in the factor VIII complex in response to DDAVP (Stimate) and concentrate infusions. Blood. 7, 362a, 1987.
13. **Sweeney JD**, Labuzetta JW, Fitzpatrick JE. ABO Blood group and platelet function. Blood. 7, 334a, 1987.
14. **Sweeney JD**, Hoernig LA, Masferrer E, Fitzpatrick JE. A study of the relationship between

platelet function in the donor and platelets pheresis harvest. *Blood*. 7, 334a, 1987.

15. Labuzetta JW, **Sweeney JD**. Absence of a direct effect of biological response modifiers on platelet function. *Blood*. 7, 353a, 1987.
16. Cohen E, Kaul N, **Sweeney JD**, Khurana U, and Farallo M. Limulus microagglutination assay of platelet sialic acid receptor display during blood bank storage. *Blood*. 7, 328a, 1987.
17. **Sweeney JD**. Whole blood platelet aggregometry. 3rd International Symposium on Recent Developments in Laboratory Hematology. Alberta, Canada. March, 1988 (Oral Presentation-Invited Speaker).
18. **Sweeney JD**, Bernstein ZP, Masferrer E, and Fitzpatrick JE. Analysis of differences in blood counts and products yields between male and female plateletpheresis donors. World Apheresis Association 2nd International Congress, Ottawa, Canada. May, 1988 (Abstract and Poster).
19. Bernstein ZP, **Sweeney JD**, Masferrer E, Hoernig LA, and Fitzpatrick JE. Absence of an effect of leukotrapping of platelet aggregation and ATP release. World Apheresis Association 2nd International Congress Ottawa, Canada. May, 1988 (Abstract and Poster) .
20. **Sweeney JD**, Labuzetta JW, Michielson C, Fitzpatrick JE. Comparison of whole blood platelet aggrego-metry using impedance and particle counter methods. *Am Sc Clin Path*. Las Vegas, Nevada. October, 1988 (Abstract and Poster).
21. **Sweeney JD**, Fitzpatrick JE, Holmberg R. Clinical differences between hemophilia A and hemophilia B. Proc. 40th Annual Meeting, Nat. Hemophilia Foundation, Anaheim, CA. October, 1988 (Abstract and Poster).
22. **Sweeney JD**, Piedmont MP, Hoernig LA, Fitzpatrick JE. The Effect of salsalate on bleeding time, platelet aggregation in whole blood and the release reaction. *Blood*. 72, 311a, 1988.
23. **Sweeney JD**, Hoernig LA, Fitzpatrick JE: Whole blood aggregation in von Willebrand's disease. *Blood*. 72, 311a, 1988.
24. **Sweeney JD**, Labuzetta JW, Fitzpatrick JE. Comparison of aggregation response of stored platelets using impedance and optical techniques. *Blood*. 72, 286a, 1988.
25. **Sweeney JD**, Novak E, Reddington D, Swank RT: Mouse model for von Willebrand's disease. *Blood*. 72, 311a, 1988.
26. Bernstein ZP, Han T, Emrich LJ, Block AW, O'Donnell A, **Sweeney JD**, Fitzpatrick JE. Karyotypic Abnormalities in chronic lymphocytic leukemia (kCLL) impact on survival. *Blood*. 72, 190a, 1988.
27. Bernstein ZP, Han T, Emrich LJ, O'Donnell A, **Sweeney JD**, Fitzpatrick JE. Serum immunoglobulin in chronic lymphocytic leukemia (CLL) relationship to cell surface immunoglobulins and impact on survival. *Blood*. 72, 190a, 1988.

28. Bernstein ZP, Han T, Emrich LJ, O'Donnell A, **Sweeney JD**, Fitzpatrick JE. Prognosis in chronic lymphocytic leukemia (CLL), analysis of 136 patients. *Blood*. 72, 190a, 1988.
29. Bernstein ZP, Cappacino A, Cappacino H, **Sweeney JD**, Fitzpatrick JE. Platelet interaction with spent media used to support tumor cell cultures. *Blood*. 72, 316a, 1988.
30. O'Donnell AM, Fitzpatrick JE, Bhargava AK, **Sweeney JD**, Santiano SA, Tin Han. Serum M-proteins in cancer patients. Submitted AACR, November, 1988.
31. Friedman N, Bernstein Z, Goldrosen M, Krajewski C, Vesper D, Steel J, Arbuck S, **Sweeney JD**, Henderson E, Takita H, Kopec I, Levitt D, Stewart C, Foon KA. Phase II trial of IL-2/LAK therapy for patients with hodgkin's disease, non-hodgkin's lymphoma and non-small cell lung cancer. Submitted ASCO, December, 1988.
32. **Sweeney JD**, Hoernig LA, Fitzpatrick JE. Changes in impedance platelet aggregation and the factor VIII/vWf complex in stored plateletpheresis products. *Proc. Am. Soc. Apheresis*, April, 1989 (Oral Presentation) .
33. **Sweeney JD**, Bernstein ZP, Masferrer E, Fitzpatrick JE. Increased platelet yield on haemonetics V-50 using five day storage sets. *Proc. Am. Soc. Apheresis*, April, 1989.
34. **Sweeney JD**. Whole blood platelet aggregation and vonWillebrand's screening. Fourth Banff symposium on innovations in laboratory technology. Banff, Alberta Canada. April, 1989 (Invited Speaker).
35. **Sweeney JD**, Delgado C, Hoernig LA, Fitzpatrick JE. ABO blood group, von Willebrand factor and ristocetin induced platelet aggregation. *Am J Clin Path*. 92; 545, 1989.
36. Garcia G, Fitzpatrick JE, Hoernig LA, **Sweeney JD**. The platelet count is a determinant of aggregation response in an optical aggregometer. *Am. J. Clin. Path*. 92, 545, 1989.
37. **Sweeney JD**, Fitzpatrick LA, Holmberg RP. Do climatic conditions influence bleeding in hemophilia A? (Poster) *Transfusion*. 30; 283, 1990.
38. **Sweeney JD**, Hardner RM. Dense body ATP and alpha-granule vonWillebrand factor in stored platelet pheresis products. *Blood*. 74; 406a, 1989.
39. **Sweeney JD**, Hoernig LA, Michnik AJ, Michielson C, Fitzpatrick JE. Abnormal clot signature in hereditary bleeding disorders. *Blood*. 74; 406a, 1989.
40. **Sweeney JD**, Lyons IC, Masferrer E, Hoernig LA, Fitzpatrick JE. P Phenotype and collagen-induced platelet aggregation in plateletpheresis products (Poster Presentation). World Apheresis Meeting, Amsterdam, April, 1990.
41. Garcia GI, Fitzpatrick JE, Stewart CC, **Sweeney JD**. The Effect of leukodepletion on glycoprotein IB expression in stored plateletpheresis products (Poster Presentation). Third International Congress World Apheresis Meeting, Amsterdam, April, 1990.

42. **Sweeney JD**, Hoernig LA, Singleton FI, Holmberg RP. Apheresis platelet transfusion in severe von Willebrand's disease (Poster Presentation). IX International Congress of the World Federation of Hemophilia, Washington, D.C., August, 1990.
43. **Sweeney JD**, Hempling R, Hoernig LA, Piver MS. Kinetic Clot parameters in gynecological tumors. *Blood*. 76; 439a, 1990.
44. **Sweeney JD**, Novak EK, Hoernig L, Swank RT. Combined deficiency of vonWillebrand factor and factor XI in the RIII/SJ mouse model. *Blood*. 76; 439a, 1990.
45. Henderson BW, **Sweeney JD**, Gessner T. Endothelial cell production of physiologic mediators in response to PDT in vitro and effects on platelet function. 19th Annual Meeting, Proc. Am. Soc. Photobiology, 1991.
46. Losonczy G, Dipirro J, Hoernig L, **Sweeney JD**, Brentjens J, Venuto RC. Pregnancy induced resistance to the thromboxane analogue U-46619 in rabbits. Prostaglandins, Leukotrienes, Lepoxins & PAF. 11th Washington International Spring Symposium, 1991.
47. Grossi M, Hoernig L, Fitzpatrick J, **Sweeney JD**. von Willebrand factor in childhood cancer (Poster Presentation) . *Am Soc Clin Onc*. 1992.
48. **Sweeney JD**, Holme S, Heaton A, Garcez R, Crong C, Nelson E, Carmen R. Preparation of leukodepleted platelet concentrates from whole blood donations using an in-line filter. *Transfusion*. 32:7S,1992.
49. **Sweeney JD**, Fitzpatrick L, Hoernig LA. Platelet function after 24 hours of storage. *Blood*. 80: 504A, 1992.
50. **Sweeney JD**, Caprio N, Hoernig LA. Reproducibility of platelet function using whole blood impedance aggregometry. *Blood*. 80:504A, 1992.
51. Heaton, A, Holme S, **Sweeney JD**, Nelson E. Use of >3 log leukoreduction of AS-3 red cells to minimize the red cell storage lesion in non-DEHP containers. *Transfusion*. 32:77S, 1992.
52. **Sweeney JD**, Holme S, Heaton A, Weisman H, Whitley P, Barachman, O'Donnell D, Herre J. Infusion of a chimeric monoclonal Fab fragment (c7E3) against glycoprotein IIB-IIIa potently inhibits platelet aggregation, but does not affect *in vivo* platelet survival. *Am College Cardiology*, Anaheim, CA. March 1993 (Poster Session).
53. **Sweeney JD**, Holme S, Heaton A. *In vivo* and *In vitro* effects of prestorage leukodepletion of apheresis platelets. *Transfusion*. 33:705, 1993.
54. Holme S, **Sweeney JD**, Heaton A, Nelson E, Carmen R. *In vivo* and *In vitro* evaluation of buffy coat platelets stored in an additive solution. *Transfusion*. 33:115, 1993.

55. Moroff G, **Sweeney JD**, Bowens ML, Tochan H, Caffey D, Yockey C. Consistency of leukocyte reduction and platelet yield in products prepared with the Cobe Spectra. *Transfusion*. 33:155, 1993.
56. Holme S, **Sweeney JD**. P-Selectin expression on platelet surface is reversible after exposure of platelets to certain adverse conditions. *Am Soc Hem. St. Louis*, December 1993 (Poster Presentation).
57. **Sweeney JD**, Holme S, Heaton A, Bowen ML, Campbell D. Pseudothrombocytopenia in platelet-pheresis donors. *Proc. 5th Int. Congress. World Apheresis Meeting, Houston, TX*. March, 1994 (Oral Presentation).
58. **Sweeney JD**, Holme S, Moroff G. Storage of apheresis platelets after gamma irradiation. *Proc. 5th Int. Congress. World Apheresis Meeting, Houston, TX*. March, 1994 (Oral Presentation).
59. **Sweeney JD**, Holme S, McCall LA, Huett D. In vivo survival of At(a+) red cells in an At(a-) recipient with anti-At^a. *Vox Sang* 67 (suppl), 113, 1994 (Poster Presentation).
60. Holme S, Heaton A, **Sweeney JD**, Sawyer S. Effect of exposure time to temperatures below 20°C on loss of platelet discoid shape during 5 day storage at 22°C. *Vox Sang* 67 (suppl) 135, 1994 (Poster Presentation).
61. Holme S, **Sweeney JD**, Sawyer S. P-selectin and GP1b as predictors of loss of platelet viability during storage. *Vox Sang*. 67 (suppl) 47, 1994 (Oral Presentation).
62. Moroff G, Holme S, Aubuchon J, Heaton A, **Sweeney JD**. Storage of red cells and platelets following gamma irradiation. *Vox Sang*. 67 (suppl) 42, 1994 (Oral Presentation).
63. Mega A, Schiffman F, Dupuis M, **Sweeney JD**. Idiopathic warm antibody autoimmune hemolytic anemia with anti-JK^a specificity. *Am. Assoc. Blood Banks, San Diego*, November, 1994 (Poster Presentation).
64. Moroff G, **Sweeney JD**, Holme S, Chopek M, Yockey C. Leukocyte (WBC) levels in plateletpheresis components: Further data. *Am. Assoc. Blood Banks, San Diego*, November, 1994 (Poster Presentation).
65. Moroff G, Holme S, **Sweeney JD**, Sawyer S, Yockey C. Evaluation of CS-3000 plateletpheresis components resuspended with a mechanical shaker. *Am Assoc Blood Banks, San Diego*, November, 1994 (Poster Presentation).
66. Smith KJ, Sierra E, Holme S, **Sweeney JD**, Nelson E. Red cell (RC) storage for 42 days in CLX^R plastic bags: In vitro characterization and in vivo survival. *Am Assoc Blood Banks, San Diego*, November 1994 (Oral Presentation).
67. Kagen LR, Aster RH, Greenwalt TJ, Lockwood W, Smith KJ, **Sweeney JD**, Ellis G, Hoff S. An integral filter for removal of leukocytes in AS-1 red blood cells. *Am. Assoc. Blood Banks, San Diego*, November, 1995 (Oral Presentation).

68. Owens M, **Sweeney JD**, Tahhan R, Fortkolt P. Effects of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenia purpura. *Blood (Suppl)* 84; 670a, 1994.
69. Tahhan HR, Whitlock AJ, Cranfill-Hupp KR, **Sweeney JD**. Red cell exchange to prevent allo-immunization to D in a 30-year-old female. *Proc Am Soc Apheresis, San Diego, CA, March 1995 (Oral Presentation)*.
70. Moroff G, Holme S, **Sweeney JD**, Luban NLC. The influence of gamma irradiation on platelets. XV Congress, International Society of Thrombosis and Hemostasis. Jerusalem, June 1995 (Oral Presentation).
71. Smith KJ, Sierra ER, Holme S, **Sweeney JD**, Elfath D, Whitley PH, Guastella MJ, Nelson EJ. Red cells in a hypotonic additive show effects of initial pH on ATP glucose consumption. AABB, 48th Annual Meeting, New Orleans, 1995 (Oral Presentation).
72. **Sweeney JD**, Saba N, CP Penn, JC Lawton, RL Yankee, MS Schanfield, C Huang. Anti-D in a Rhesus positive renal transplant patient. *Blood*. 86 (Suppl 1), 852a, 1995.
73. Arduini A, Holme S, **Sweeney JD**, Calvani M. Possible role of L-carnitine in improving in vitro and in vivo properties of red cells stored at 4°C. *Blood*, 86 (Suppl), 545a, 1995 (Poster Presentation).
74. **Sweeney JD**, Penn LC, Camara P, Yankee R, Petrucci J. Differences in measured potency of pheresis products between Blood Center and Hospital Transfusion Services. *Proc Am Soc Apheresis. Santa Fe, NM, March, 1996 (Oral presentation)*.
75. **Sweeney JD**, Dupuis MP, England K, Blair AJ, Kim J, Thiesen L. Perioperative autologous platelet harvesting may maximally benefit certain subpopulations of patients undergoing open heart surgery. *Proc Am Soc Apheresis, Santa Fe, NM, March, 1996 (Oral presentation)*.
76. **Sweeney JD**, Dupuis MP, England K, Kim J, Moulton A. Potency of autologous platelets in cardiac surgery and allogeneic transfusion (oral presentation). *Proc. World Apheresis Assoc., Florence, Italy, November, 1996*.
77. **Sweeney JD**, King TC, Moulton A. Aprotinin decreases activated protein C resistance ratio in normal plasma. *Blood*. 88(10), Suppl. 1, 86b, 1996.
78. **Sweeney JD**, Blair AJ, King TC. A comparison of Russel Viper Venom time and activated partial thromboplastin time based screening tests for FV Leiden. *Blood* 88 (10), Suppl. 1, 86b, 1996.
79. Akhtar M, Blair AJ, King TC, **Sweeney JD**. Whole Blood Russel Viper Venom Time Assay as a screening test for Factor V Leiden. *Am. J. Clin. Pathol.* 108:347-348, 1997
80. **Sweeney JD**, Blair AJ, Arduini A, Petrucci J. L-Carnitine attenuates the deleterious effects of gamma irradiation on red blood cells (poster presentation). 25th Congress of the International Society of Blood Transfusions. Oslo, Norway. June, 1998.

81. **Sweeney JD**, Blair AJ, Arduini A, Petrucci J. L-Carnitine and L-Acetyl carnitine may reduce glycolysis in stored platelet concentrates (Poster Presentation). 25th Congress of the International Society of Blood Transfusion. Oslo, Norway. June, 1998.
- 82.
83. **Sweeney JD**, Penn LC, McHugh KE, Nelson EJ, Oblon DJ. Prestorage Leukoreduced random donor platelets in Autologous bone marrow transplant patients (Oral Presentation). 25th Congress of the International Society of Blood Transfusion. Oslo, Norway. June, 1998.
84. **Sweeney JD**, Blair AJ, Cheves TM, Arduini A. L-Carnitine decreases glycolysis in prestorage gamma irradiated platelets (Poster Presentation). AABB, Philadelphia PA October 1998 Transfusion. 38: (Suppl) 295, 1998.
85. **Sweeney JD**, Blair AJ. Measurement of extent of shape change and hypotensive shock response using a novel device (Poster Presentation). AABB, Philadelphia PA October 1998 Transfusion. 38: (Suppl) 285, 1998.
86. Estalilla OC, King TC, Dumenco LL, Luciani A, **Sweeney JD**. Molecular genetic analysis of the thermolabile metylenetetrahydrofolate reductase gene among patients undergoing cardiac bypass surgery (Oral Presentation). Am J Clin Path. 110: 511-512, 1998.
87. Estalilla OC, King TC, Dumenco LL, Luciani A, **Sweeney JD**. Factor V Leiden and polymorphism in the 3¹ untranslated region of the prothrombin gene among patients having coronary artery bypass surgery (Oral Presentation). Am J Clin Path. 110: 540, 1998.
88. **Sweeney JD**, Blair AJ, Veriabo N. Preoperative impedance aggregometry correlates with post operative chest tube drainage in cardiac surgery (Poster Presentation). 52nd Annual Meeting – AABB, San Francisco, November, 1999.
89. **Sweeney JD**, Cheves TA, Dottori S, Arduini A. L-carnitine reduces glycolysis in extended stored prestorage leukoreduced random platelets (Poster Presentation). 52nd Annual Meeting – AABB, San Francisco, November, 1999.
90. **Sweeney JD**, Cheves TA, Arduini A. L-carnitine may suppress bacterial growth in extended stored platelet concentrates (Poster Presentation). 52nd Annual Meeting – AABB, San Francisco, November, 1999.
91. **Sweeney JD**, Tigges JC, Kouttab NM. Characterization of residual leukocyte subsets in pools of prestorage leukoreduced whole blood derived platelets (Oral Presentation). 26th Congress of the International Society of Blood Transfusion. Vienna, Austria, July, 2000.
92. **Sweeney JD**, Cheves TA, Arduini A. L-carnitine reduces glycolysis and improves pH in apheresis platelets stored for 10 days (Oral Presentation). 26th Congress of the International Society of Blood Transfusion. Vienna, Austria, July, 2000.
93. Mangray S, Dupuis M, **Sweeney JD**. Routine Monitoring of blood pressure is not useful in Transfusion recipients. (Poster Presentation). 26th Congress of the International Society of Blood Transfusion. Vienna, Austria, July, 2000.

94. Stancu M, **Sweeney JD**. Should predeposit autologous blood be leukoreduced? 53rd Annual meeting of the American association of Blood Banks. Washington DC. Novemebr, 2000 Transfusion. 2000;40: 8S.
95. **Sweeney JD**, Arduini A, Tigges J, Cheves TM, Kouttab N. L-carnitine reduces hemolysis in prestorage leukoreduced red blood cells (Oral Presentation). International Society of Blood Transfusion, Regional Meeting. Paris, July, 2001.
96. **Sweeney JD**. Impact of Universal Leukoreduction on Requests for CMV Seronegative Blood Products. Transfusion. 41, S34, 2001 (Poster Presentation).
97. **Sweeney JD**, Conti G. Decreased length of stay in DRG 148 after implementing Universal Leukoreduction. Transfusion. 41, S38, 2001 (Poster Presentation)
98. **Sweeney JD**, Conti G. Decreased length of stay in DRG 210 after implementing Universal Leukoreduction. Transfusion. 14, S39, 2001. (Poster Presentation).
99. **Sweeney JD**. Decrease in Reaction Rates after implementing Universal Leukoreduction. Transfusion. 41, S268, 2001 (Poster Presentation).
100. **Sweeney JD**, Kouttab N, Arduino A. L-Carnitine decreases surface expression of phosphatidyl serine and improves morphology in extended stored platelets. 27th Congress of the International Society of Blood Transfusion. Vancouver, Canada, August, 2002 (Oral Presentation).
101. Chai L. **Sweeney JD**. Interdictions of pre-procedure plasma in patients with coagulaopathy undergoing invasive procedures (Poster Presentation). AABB 55th Annual Meeting, Orlando, FL October 2002.
102. **Sweeney JD**, Cheves TM, Sweeney JA, Kouttab N. Red Cell Microvesicles which form during red cell storage express phosphatidylserine (Poster Presentation). AABB 55th Annual Meeting, Orlando, FL. October, 2002. Transfusion. 42: 53S, 2002.
103. **Sweeney JD**, Kouttab N, Sawicki F. Dose response of the beneficial effect of l-Carnitine on the storage lesion of prestorage leukoreduced red cells (Poster Presentation). AABB 55th Annual meeting. Orlando, FL. October 2002.
104. **Sweeney JD**, Kouttab NM, Kurtis JD, Cheves TC, Holme SH, Nelson EJ. Prestorage pooled whole blood derived platelets stored to seven days preserve in vitro function and do not show a mixed lymphocyte reaction (Oral Presentation). AABB 56th Annual meeting, San Diego, Ca. October 2003.
105. **Sweeney JD**, Kouttab N, Sawicki F. Surface Expression of phosphatidylserine shows an inverse relation with surface glycoprotein 1b in stored platelets (Poster Presentation). AABB 57th Annual Meeting, Baltimore, MD. October, 2004
106. **Sweeney JD**, Cheves T. Use of the Thromboelastogram in the in vitro evaluation of platelet

- quality (Poster Presentation). AABB 57th Annual Meeting, Baltimore MD October 2004.
107. Blair A, Martin C, Popovsky M, Cheves T, **Sweeney JD**. Postmarket validation of the quality of stored platelet products collected with SDP software Rev.E (Poster presentation). 28th Congress of the International society of Blood Transfusion, Edinburgh U.K. July, 2004.
 108. **Sweeney JD**, Kouttab N, Cheves T, Kurtis J, Holme S, Nelson E. Prestorage Pooled whole Blood derived Platelets maintain acceptable in vitro function to day 7. XV Regional Meeting, ISBT, Athens, Greece. July, 2005.
 109. Carlsten J, Cochrane S, Pilz J, **Sweeney JD**. Extended Phenotyping of Patient Samples and Donor Cells Using Automated Technology (Poster Presentation). AABB 58th Annual Meeting, Seattle, WA. October, 2005. Transfusion. 2005; 45: 137A.
 110. LeGolvan M, Pilz J, **Sweeney JD**. Should Patients with Malignancies receive Phenotyped Matched Red Cells? Poster Presentation, AABB 58th Annual Meeting, Seattle, WA. October, 2005. Transfusion. 2005; 45: 132A
 111. **Sweeney JD**, Kouttab N, Cheves T, Kurtis J, Holme S, Nelson E. Whole Blood Platelet Rich Plasma Derived Pools stored in Additive Solution Preserve Good Function to 7 Days. Oral Presentation, AABB 58th Annual Meeting, Seattle, WA. October, 2005. Transfusion. 2005; 45: 30A
 112. **Sweeney JD**, VanHouten PT, Daniels LJ, Martin CR, Rose LE, Popovsky MM, Rose MA. Validation of local pain medication processing efficiency with a surgical salvage device. ASFA, 27th annual meeting, Las Vegas, NV. May 2006. J Clin Apheresis. 21: 24, 2006.
 113. Laga A, Cheves TC, **Sweeney JD**: The Effect of Specimen Hemolysis on Coagulation Tests (Poster presentation). ASCP Meeting, Las Vegas, 2006.
 114. **Sweeney JD**, Kouttab N, Cheves T, Holme S, Nelson E. Prestorage pools consisting of non-ABO identical platelet concentrates preserve good function to seven days storage. (Oral presentation). AABB Miami October 2006. Transfusion. 46 : 24A, 2006
 115. **Sweeney JD**, Prestorage pools consisting of hyperconcentrated platelets can be stored for five days in CLX-HP containers. Cheves T, Holme S, Nelson E. (Poster Presentation). AABB Miami October 2006) Transfusion. 46 : 68A, 2006
 116. **Sweeney JD**, Arduini A, Holme S, L-carnitine reduces hemolysis and maintains pH to day 7 in hyper concentrated platelets (poster presentation, ISBT Madrid, 2007) Vox Sang 93: (Supp 1) 109, 2007
 117. Laga A, **Sweeney JD**: Recurrent TRALI in FV Deficiency. (Poster Presentation). ISBT, Macao, China, June 2008.
 118. **Sweeney JD**, Cheves TC: Clinical Experience with Whole Blood Derived prepooled Platelets Manufactured from Platelet rich Plasma. Oral presentation, AABB, Montreal, Canada, October

2008. *Transfusion*. 48: (Suppl), p13a.
119. **Sweeney JD**, Roberts L: Second specimen for ABO confirmation can impact red cell inventory management. Oral presentation, AABB, Montreal,. Canada. October, 2008. *Transfusion*. 48: (Suppl), p27a.
 120. Asad S, Mermel L, **Sweeney J**. Transfusion Transmitted Babesiosis in Rhode Island. Oral presentation, AABB, Montreal, Canada. October, 2008. *Transfusion*. 48 (Suppl), p32a.
 120. **Sweeney JD**, Cheves TC. 24 Hour Room Temperature Frozen Plasma Retains All Clotting Factor Levels After Thawing , Except FVIII, to Day 7. Poster presentation. AABB, New Orleans, October 2009 *Transfusion*. 49: (Suppl), p80 a
 121. Vassallo R, Einarson M, Nixon J, Ziegler DH, **Sweeney JD**, Cheves TA. In vitro evaluation of Whole Blood Derived Platelets suspended in Plasma or a Glucose –Containing Additive Solution. Poster presentation. AABB, New Orleans, October 2009. *Transfusion*. 49: (Suppl), p85 a.
 122. Tsapenko AV, **Sweeney J**, Carino G. Fresh frozen plasma use before line-insertion in critically ill patients with coagulation abnormalities. *Crit Care Med*. 2009; 37 (Suppl): A955. Alhumaidan H,
 123. Cheves T, Holme S, Nelson EJ, **Sweeney JD**. A comparison of Platelet Storage in plasma to platelets stored in a glucose containing additive solution. Poster presentation, ISBT, June 2010 Berlin Germany. *Vox Sang*. 99 (suppl 1) p209, 2010.
 124. Alhumaidan H, Cheves T, Holme S, **Sweeney JD**. Stability of Cloting factors after 24 hour Room Temperature Hold. Oral Presentation. AABB, Baltimore MD October 2010. *Transfusion*. 50: 8A-9A, 2010.
 125. Syed J, **Sweeney JD**. No Relation Between the Storage Age of Allogeneic Red Cells Transfused in Cardiac Surgery and Post-operative length of Stay. Oral Presentation. AABB, Baltimore, MD, October 2010. *Transfusion*. 50: 27-28A, 2010.
 126. Tavares M, **Sweeney JD**. Decrease in Red Cell Transfusion after Enforcement of Transfusion Guidelines. Accepted. Poster presentation. 21st Regional Congress of the ISBT. Lisbon, Portugal, June, 2011.
 127. Pinheiro L, **Sweeney JD**. Two cases of TRALI from Red cell Concentrates containing anti-HLA class II Antibodies. Accepted. Oral presentation. 21st Regional Congress of the ISBT. Lisbon, Portugal, June 2011.
 128. Meehan R, Tavares M, **Sweeney JD**. Plasma avoidance using Intravenous Vitamin K. Poster presentation, AABB. San Diego, October 2011.
 129. Alhumaidan H, Cheves T, **Sweeney JD**. The effect of leukoreduction filtration on clotting factors in thawed plasma. Poster presentation, AABB. San Diego, October 2011.

130. Roberts L, Keane M, **Sweeney JD**. Partial signature is superior to Initials Only in identifying a phlebotomist but both Approaches have a high failure rate. Poster presentation, AABB. San Diego, October 2011.
131. Alhumaidan H, Cheves T, Holme S, **Sweeney JD**. Cryoprecipitate and cryosupernatant from frozen plasma manufactured using a 24 hour room temperature hold. Poster presentation, AABB. San Diego, October 2011.
132. Alhumaidan H ,Westley B,Esteva C, Berardi B, Young C, **Sweeney JD**. Transfusion Transmitted Anaplasmosis from a leukoreduced red cell. Transfusion. 2012, 52S: 3S; 54A. Oral presentation, AABB. Boston MA, October 2012.
133. Alhumaidan H, Cheves T, Holme S, **Sweeney JD**. Effect of Filtration on Clotting Factors Levels Transfusion. 2012, 52S: 3S; 54A. Poster presentation, AABB. Boston MA, October 2012.
134. Alhumaidan H, **Sweeney JD**. Intravascular hemolysis from liquid IVIG may be caused by Anti A,B antibody. Transfusion. 2012, 52S: 3S; 178A. AABB. Boston MA, October 2012.
135. Perincheri S, Schultz G, Krohto S, **Sweeney JD**. A study of the utility of ficin in antibody identification . Transfusion. 2012, 52S: 3S; 105A. Poster presentation, AABB. Boston MA, October 2012.
136. Mehri D, Roberts L, George A, Stephen A , **Sweeney JD**. Evaluation of a point-of-service smart refrigerator to optimize the immediate availability of red cells and thawed plasma. Transfusion. 2012, 52S: 3S; 261A. Poster presentation, AABB. Boston MA, October 2012
137. Alrabeth R, Krohto S, **Sweeney JD**. Comparison of the Tube and gel method in testing for ABO incompatibility. Transfusion. 2012, 52S: 3S; 146A. Poster presentation, AABB. Boston MA, October 2012.
138. Tavares M, **Sweeney JD**. An Analysis of single Unit Red cell Transfusion. Transfusion 2013; 53 2A. Poster presentation, SABM , Los Angeles, September 2013
- 139: Tavares M, DiQuattro P, **Sweeney JD**. Encouraging Single Unit Red Cell Transfusion Prescription for In-Patients can be Effective in Reducing Red Cell Usage. Poster presentation, AABB , Denver CO, October 2013
140. Chen S , **Sweeney J**. **Irradiation of Cellular Components for Pediatric patients: can leukoreduction alter Practices**. Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 133A, 2014
141. Piskorski A, **Sweeney J**. Intravascular Hemolysis form prepooled platelets. Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 143A, 2014
142. Li J, **Sweeney J**. Total loss of the A antigen in Acute Myeloid leukemia. Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 158A, 2014

143. Chen S, Krohto S, Roberts LD, Stachurski D, Williams C, Milbrandt-Pohan S, **Sweeney J.** Cord blood testing using an Automated column Agglutination Method. Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 158A, 2014
144. Krohto S, Roberts LD ,Cheves T, **Sweeney J.** False negative compatible Antiglobulin crossmatches in patients with a positive indirect antiglobulin test and an alloantibody to a cognate antigen. Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 158A, 2014
145. Clubwala R, **Sweeney J.** Bacterial sepsis from platelets in Rhode island: 1999-2013 Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 203A, 2014
146. Gultawatvichai P, Tavares MF,Cheves T, **Sweeney J.** Hemolysis form additive stored red cells may exceed 1%. Poster presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 69A, 2014
147. Schultz E, Roberts LD, **Sweeney JD.** Remote Blood bank dispensing in Operating room without a Blood bank interface. Oral presentation, AABB , Philadelphia Pa , October 2014. Transfusion. 54, 227A, 2014
148. Butler JT Roberts LD, **Sweeney JD.** Training Surgical Staff for a successful implementation of Remote Blood bank dispensing in Operating room. Poster presentation, AABB , Philadelphia Pa, October 2014. Transfusion. 54, 243A, 2014

INVITED PRESENTATIONS:

INTERNATIONAL:

Whole Blood Platelet Aggregometry. 3rd International Symposium on Recent Developments in Laboratory Hematology, Alberta, Canada, March, 1988/

Whole Blood Platelet Aggregation and vonWillebrand Disease. Fourth Banff Symposium on Innovations in Laboratory Technology, Alberta, Canada, April, 1989.

Hemostasis Abnormalities in Cancer Patients. Hemostasis and Thrombosis Symposium Ortho Diagnostics, Raritan, New Jersey – October, 1991.

Platelet Quality Assessment: Twelfth International Convocation on Immunology; Buffalo, NY. May, 1994.

Blood Transfusion in Cardiac Surgery. Focus on Red Cell Pathophysiology. Perugia, Italy, May, 1995.

Perioperative Autologous Component Harvesting In Cardiac Surgery. International Society of Blood Transfusion, 24th Int. Congress, Tokyo, Japan. April, 1996.

Cost Effectiveness of Leukodepleted Blood. 15th Annual Meeting of the Korean Society for Blood Transfusion. Yoo Sung, Korea. May, 1996.

Random donor or Apheresis Platelets. Consensus Conference on Platelet Transfusion. Ottawa, Canada. May, 1998.

Quality Assurance and Standards for Red Cells and Platelets. 25th Congress of the International Society of Blood Transfusion, Oslo, Norway. June, 1998.

Blood Transfusion in Cardiac Surgery. 1st Annual Symposium of Transfusion Medicine. Cairo, Egypt. March, 1999.

Clinical Indications for Blood Components- Platelets: 10th Annual Congress of the Spanish Society of Blood Transfusion, Madrid, Spain. May, 1999.

Universal Leukocyte Reduction of the Blood Supply. 32nd Annual Meeting of the German Society for Transfusion Medicine and Immunohematology. Münster, Germany. October, 1999.

Blood Transfusion in Cardiac Surgery: Regional Transfusion Medicine Congress, Cairo, Egypt. March, 2006

Alternatives to Blood Transfusion, Sixth Pan-Arab Conference on Blood Transfusion, Riyadh, Saudi Arabia, February, 2007.

Blood Transfusion in Cardiac Surgery: Sixth Pan-Arab Conference on Blood Transfusion, Riyadh, Saudi Arabia, February, 2007.

Control of Blood Utilization: 10th Annual meeting of the Norwegian Red Cross (co-sponsored by Brown University), Oslo , Norway, May, 2007.

The Blood Bank Director as a Hemostasis Consultant. 10th Annual meeting of the Norwegian Red Cross (co-sponsored by Brown University), Oslo , Norway, May, 2007.

Advantages and Disadvantages of Whole Blood versus Apheresis platelets. Seventh Pan-Arab Conference on Blood Transfusion, Doha, Qatar, February, 2009.

Massive Transfusion, Seventh Pan-Arab Conference on Blood Transfusion, Doha, Qatar , February, 2009.

Red Cell storage lesion: V Congreso Peruano de Medicina Transfusional. Lima, Peru. September, 2009.

The Platelet storage lesion: V Congreso Peruano de Medicina Transfusional Lima, Peru. September, 2009.

Whole blood derived or apheresis platelets? V Congreso Peruano de Medicina Transfusional . Lima, Peru. September, 2009.

Massive Blood Transfusion. Symposium on Clinical Transfusion Medicine, Riyadh, KSA, September, 2010.

Platelet Quality : What is important for the Blood bank, the Hospital and the Patient. Symposium on Clinical Transfusion Medicine, Riyadh, KSA, September, 2010.

Is Thrombosis a complication of Red Cell Transfusion. Symposium on Clinical Transfusion Medicine, Riyadh, KSA, September, 2010.

Blood Transfusion Workshop: Kuwait City, Kuwait. April 26-28th, 2015

NATIONAL:

Diagnosis in Whole Blood of Platelet Dysfunction, 24th Annual Blood Coagulation Course, Michigan State University, Lansing, May, 1990.

American Society of Clinical Pathologists: Sole Presenter: National Teleconference on "Whole Blood Platelet Lumi-Aggregometry." October 20, 1992.

The Random Donor Platelet 49th Annual Meeting of the American Association of Blood Banks, Orlando, FL, October, 1996.

Update of Leukoreduction. 50th Annual Meeting of the American Society for Blood Banks, Denver, CO, October, 1997.

Leukoreduction: Methods and Quality Control. 51st Annual Meeting of the American Association of Blood Banks, Philadelphia, PA, 1998.

Universal Leukoreduction: 52nd Annual Meeting of the American Association of Blood Banks, San Francisco, CA, November, 1999.

AABB Teleconference: Leukoreduction. August 10th, 2000.

Platelet Dosing. 54th Annual Meeting of the AABB , San Antonio, TX . October, 2001.

Hypercoagulability American College Physicians- Meet the Professor — New Orleans, April 2004.

Experience with Bacterially Tested Whole Blood Derived Platelets, Prestorage Pooling and the Utility of First Sample Pouch Diversion . 59rd Annual Meeting of the AABB , Miami, Florida, October, 2006.

Advanced Coagulation Case Series - American Medical Technologists 70th Annual meeting- Providence, RI July, 2008.

New developments in Platelet Testing- 61rd Annual Meeting of the AABB, Montreal, Canada.

October, 2008.

Prophylactic Platelet Transfusions prior to an invasive Procedure. 63rd Annual Meeting of the AABB, Baltimore, MD. October, 2010.

Platelet Additive Solutions. ASFA annual meeting, Scottsdale AZ. June, 2011.

Platelet Transfusion for Physicians- 62nd Annual meeting of the AABB, San Diego, CA. October, 2011.

Control of FFP transfusion. Patient Safety symposium. 62nd Annual meeting of the AABB, San Diego, CA. October, 2011.

The Epidemic of Plasma Transfusion: Stemming the Tide. 20th Annual meeting of SABM, Pittsburgh, PA, September, 2012.

Overuse of plasma. ASCP National Teleconference, 8th May, 2013.

Reducing Plasma Transfusion. Geisinger Health Systems, Danville Pa. 22nd, October 2014

Fresh Frozen Plasma: Peril or Therapeutic Pearl. Patient Blood Management Symposium, Kansas City, April 15th, 2015

Emerging Pathogens in the Blood Supply. SABM National Meeting, Orlando, FL. September, 2015

REGIONAL OR STATE:

Congenital Bleeding Disorder, Empire State Medical Technologist Meeting, Buffalo, New York, April, 1987.

Newer Products in the Treatment of Hemophilia, New York State Blood Bankers Meeting, Buffalo, New York, June, 1989.

Aggregation of Platelets in Whole Blood, Empire State Medical Technologist, Albany, New York, April, 1990.

Management of Hemophiliacs, Empire State Medical Technologists, Buffalo, New York, April, 1991.

Technological Innovations in the Treatment of Hemophilia. New York State Blood Bankers Meeting, Rochester, New York, April, 1992.

Quality of platelet products. Rhode Island Blood Bankers Society Meeting, Providence, RI, September, 1994.

Prestorage leukodepletion of blood products. American Clinical Laboratory Science; Central New England Meeting. Marlboro, MA, March, 1995.

Thrombophilic states. Rhode Island Chapter of the American College of Physicians. Newport, RI, October, 1995.

Leukodepletion and the attenuation of microbial transmission by blood transfusion. Massachusetts Assoc. Blood Banks, Westford, MA, April, 1996.

Leukoreduction: Current concepts and future possibilities. Transfusion Medicine 1996: State of the Art. Sturbridge, MA. December, 1996.

Guidelines for the use of fresh frozen plasma. 20th annual meeting of the Mid-Atlantic Association of Blood Banks. Baltimore, MD. April, 1997.

Leukodepletion: Current practice and future implications: American Red Cross Regional Transfusion Medicine Conference. Augusta, ME. May, 1997.

Current states of Leukodepleted blood products. Annual Clinical Laboratory Science Society of Central New England. Providence, RI. May, 1998.

Quality Assurance and standards for red cells and platelets: USA versus Europe. Rhode Island Blood Bankers Society Meeting. Providence, RI, September, 1998.

Thrombophilic States: Recent developments. Rhode Island Chapter of the American College of Physicians. Newport, RI. October, 1998.

Leukoreduction of Red Cells. 22nd Annual Meeting of the Mid-Atlantic Association of Blood Banks, Rensselaer, VA. April 1st, 1999.

Universal Leukoreduction in Rhode Island. CLS/CNE 51st Annual Meeting, Providence, RI. April 6th, 1999.

Hypotension Reactions in Transfusion Recipients. Massachusetts Association of Blood Banks, Westford, MA. May 3rd, 1999.

Red Cell Transfusion. Transfusion Medicine 2000. Sturbridge, MA. October 25th, 2000.

Hypercoagulability 2000. Rhode Island Chapter of the American College of Physicians. Newport, RI. November, 2000.

Impact of Leukoreduction in Rhode Island. Massachusetts Association of Blood Banks. Westford, MA. May 6th, 2001.

Plasma Transfusions: Products, Policies and Policing. New York State Blood Bankers Meeting. Albany, NY. June 1st, 2001.

Hypercoagulability: Meet the Professor. Rhode Island Chapter of the American College of physicians. Providence, RI May 3rd, 2002.

Blood Utilization in Rhode Island. Massachusetts Association of Blood Banks. Westford, MA. May, 8th, 2002.

Hypercoagulability: Rhode Island Chapter of the American College Physicians, Providence, RI May, 16th, 2003.

Residual Risks of Blood Transfusion CLS/CNE Providence , RI May 6th , 2003.

Automation in the Blood Bank. Applied Management Systems, Meeting on Laboratory Automation, Needham, MA. February 10th, 2004

Hypercoagulability - the Thrombophilic States: Meet the Professor. Annual meeting of the American College of Physicians, New Orleans, LA . April 24th, 2004.

The future of Whole Blood Derived Platelets, CLS/CNE, May, 2004.

Blood Filters: What can we filter and how? Illinois State Blood Bankers Meeting, Chicago, IL April 15th, 2005.

Blood Filters: What can we filter and how? Mass Assoc Blood Banks, Westford, MA , April 26th, 2005.

Hypercoagulability: CLS/CNE, Providence, RI , May, 2005.

Acquired Hypercoagulability : Rhode Island Chapter of the American College Physicians, Newport , RI October 19th, 2005.

Alternatives to Blood Transfusion. CLS/CNE, Providence, RI, May, 2007.

Workshop on Coagulation Testing. CLS/CNE, Providence, RI, May, 2007.

Anti-Platelet drug testing. CLS/CNE, Providence, RI , May, 2008.

Experience with Prepooled Whole blood Derived Platelets. Tennessee Blood bankers Association, Nashville, May, 2008.

Clinical Experience with Prepooled Whole blood Derived Platelets. New Jersey Blood bankers association, New Brunswick, May, 2008.

Red wine, red cells and thrombosis. Regional meeting SABM, Providence, RI March, 2009.

Transfusion Transmitted Babesiosis. CLS/CNE, Providence, RI , May, 2009.

Platelet Additive Solutions. CLS/CNE, Providence, RI, May, 2010.

Whole Blood derived or Apheresis Platelets: Current Status. Harvard Transfusion Medicine Fellowship Grand Rounds, Boston MA, March, 2011.

Whole Blood Derived platelets. SCABB meeting, Las Vegas NV, April, 2011.

Evidence based Plasma Therapy. 2nd University of Pittsburgh Medical Center Conference on Patient Blood Management; Pittsburgh, PA. November, 2011.

The Choice of Apheresis or Whole blood derived Platelet Pools: New York State Blood bankers meeting, New York, New York, June, 2012.

Are Whole Blood pooled Platelets better than Apheresis platelets . Mass Assoc blood banks meeting, Westford, MA April 23rd, 2013

Comparison of Whole Blood derived and Apheresis platelets. CLS/CNE meeting, Providence , RI May 7th, 2013

Transfusion of FFP. Northeast laboratory meeting, Portland ME . October ,2013

Patient Blood management: the Rhode Island Experience. CLS/CNE meeting, Providence , RI April 30th, 2014

The New Anticoagulants : Rhode Island Chapter of the American College Physicians, Cranston, RI May, 8th 2014

SYMPOSIA ORGANIZED:

Program Director, First Annual Advances in Transfusion Medicine Symposium, Norfolk, VA May 1992. Co-sponsored by Eastern Virginia Medical School and American Red Cross.

Program Director, Second Annual Advances in Transfusion Medicine Symposium, Norfolk, VA May 1993. Co-sponsored by Eastern Virginia Medical School and American Red Cross.

Co-Chairperson: Regional Transfusion Medicine Congress, Cairo, Egypt. March 2006.

Co-Chairperson: 10th Annual meeting of the Norwegian Red Cross (co-sponsored by Brown University), Oslo , Norway, May 2007.

Program Director. New Frontiers in Transfusion Medicine. Providence RI and Brown University, April 2010.

Program Director. International Symposium on the Science of Platelet Transfusion. Providence RI and Brown University, October 2012.

GRANTS AWARDED - PRINCIPAL INVESTIGATOR:

July - 1984 - Veterans' Administration Medical Center - Studies of Coagulation in Cancer Patients - \$1,800.

March - 1985 - Armour Pharmaceuticals - Platelet Function in Hemophilia A - \$3,000.

July - 1985 - Riker Pharmaceuticals - Study of Salsalate in Hemophilia - \$8,000.

July - 1985 - Dupont Pharmaceuticals - Study of Warfarin Formulation on Anti-Coagulant Control - \$2,000.

December - 1985 - James H. Cummings Foundation - Coagulation Equipment - \$20,300.

March - 1986 - Armour Pharmaceuticals - Study on DDAVP and von Willebrand Factor Response - \$3,000.

January - 1986 - Buffalo Forge Foundation - Equipment Purchase - \$1,300.

March - 1988 - Buffalo Foundation - Equipment Purchase - \$5,000.

July - 1988 - Riker Pharmaceuticals - Studies of Salsalate on Bleeding and Platelet Function - \$11,500.

January - 1989 - Cutter Biologicals - Effects of prestorage Leukodepletion on Platelet Storage Injury - \$33,750.

December - 1989 - Ortho Diagnostics - Studies of Clot Signature in Hereditary Bleeding Disorders \$9,000.

November - 1990 - Association Research of Childhood Cancer - (AROCC) von Willebrand Factor in Pediatric Malignancies - \$9,750.

December - 1990 - James H. Cummings Foundation - Platelet Aggregometer - \$20,000.

July - 1991 - Dupont Pharmaceutical - The anticoagulant effect and safety of adjusted doses of Coumadin^R/plus 80 mg ASA compared to 320 mg aspirin in patients with coronary artery disease - \$38,000.

June - 1992 - American Red Cross - Effects of prestorage leukodepletion on apheresis platelets - \$33,200.

June - 1992 - Centacor - A study of the effect of c7E3 on *in vivo* platelet survival and platelet distribution - \$154,900.

April - 1993 - American Red Cross - Effects of Gamma Irradiation on Stored plateletpheresis products - \$35,000.

August - 1993 - Miles, Inc. - AS-22 as a red cell preservative - \$50,000.

December - 1994 -1999 - NHLB1 - HB-94-12 - Viral activation transfusion study. Co-Investigator (10%). - \$839,000.

March - 1995 - P.I.- Bayer, Inc. - Leukodepleted Blood in Cardiac Surgery. - \$97,000.

April - 1995 - co-P.I.- Bayer, Inc. - Activated Protein C Resistance in Cardiac Surgery. Co-Investigator

- \$20,000.

May - 1995 - P.I.- Merocel Inc. - Studies on the surface interaction of sponge material and the coagulation-hemostasis System. - \$15,000.

January - 1996 – P.I. Medsep Inc. - Comparison of platelet count increments and adverse reactions using prestorage leukodepleted platelet concentrates and standard platelet concentrates in thrombocytopenic patients. - \$58,000.

January - 1997 - -P.I. Sigma-tau Corporation - A study of the role L-carnitine and acylated derivatives in ameliorating the red cell membrane defect associated with gamma irradiation and the platelet storage injury. - \$154,000.

September – 1998 –P.I. PALL Corporation – Leukocyte subsets in prestorage Leukoreduced random donor platelets. - \$36,700.

August – 1999 – P.I. Carter Wallace Inc. – A study of the effect of taurolidine on platelet function and bacterial growth in liquid stored platelet concentrates. - \$55,700.

August – 2001 – P.I. -Sigma-tau Corporation – Red cell microvesiculation during storage. Effects of L-carnitine. \$52,940.

March –2003- P.I.- PALL Corporation- Comparison of prestorage versus post storage pooling of whole blood derived platelet concentrates- \$102,960.

March- 2003- P.I. – Haemonetics Corporation- A Study of the SDPD versus the SDPE protocol for plateletpheresis - \$29,700.

October 2004- PI- PALL Corporation- Study of Pooled platelet storage in a new container (ELX)- \$120,000.

April, 2005- PI - PALL Corporation- Additive Solutions with prestorage pooled whole blood derived platelets. \$25,000.

March 2006: P.I. PALL Corporation: Evaluation of the CLX-HP Storage Bag and the Use of Mixed A and O Platelets. \$78,213.

February: 2007: P.I. PALL Corporation Post market evaluation of prestorage pooled whole blood derived platelets. \$22,500.

November 2008 .P.I. PALL Corporation: In Vitro evaluation of platelets suspended in either plasma or PAS-G additive solution. \$226,000.

March 2009 PI. PALL Corporation: Evaluation of plasma processed and stored in Covina made Euro set (top&top, cpd/sag-m) system as compared to Ascoli made set. \$34,000.

March 2011: PI . Smiths Medical: Effect of a new gas vent filter on red cells Hemolysis and plasma clotting factors: \$58,300.

August 2012: PI. Studies on the effect of PER977 on coagulation and hemostasis. Persphere Inc \$15,000.

October 2012: PI . Evaluation of the IH-1000 for automated compatibility testing. Bio_Rad Corp. Dietrick, Germany \$186,341.

UNIVERSITY TEACHING EXPERIENCE:

Teaching Awards:

Brown University Pathology Residents: Outstanding Teaching in Transfusion Medicine Award 2002-2003

Brown University: Dean's Teaching Excellence Award. 2003

Brown University Hematology-Oncology Fellows: Teacher of the year Award 2003-2004

Brown University Pathology Residents: Best Teacher in Pathology Award 2007-2008

Medical Staff, Miriam Hospital: Marcia C Reisman Award for Excellence in Teaching 2010

State University of New York at Buffalo (SUNYAB): 1986-1991

Sole Lecturer & Course Coordinator: Coagulation and Hemostasis: M.S. Degree course, Medical Technologists 1986, 1988, 1989 and 1991 (21 Contact Hours per year).

Lecturer: Coagulation and Bleeding Disorders: Lectures for 2nd year Medical Students 1989, 1990, and 1991 (2 Contact Hours per year).

Eastern Virginia Medical School (EVMS): 1992-1994

Course Coordinator: Hematology (28 Contact Hours per year), 2nd year medical students. 1992 and 1993.

Lecturer: Transfusion Medicine; Hemostasis; Anemia's

Brown University School of Medicine: 1995 – Present

Medical Students:

Lecturer: Hematology - Pathophysiology course and small group facilitator, 1995. (17 Contact Hours)

Lecturer: Hematology - Pathophysiology course, 1996 – 2005. (2 Contact Hours per year)

Lecturer; Principles of Transfusion Medicine: Pathophysiology course, 2005– 2013 (1 Contact Hour per year)

Residents and Fellows:

Lecturer: *Coagulation Course. A series of 13 lectures.* A comprehensive series of lectures on basic and applied aspects of coagulation for Clinical Pathology Residents, and Hematology-Oncology Fellows. 2001-2002; 2004; 2006, 2007, 2009

Lecturer: *Transfusion Medicine: A series of 11 lectures.* A series of lectures intended for Clinical Pathology residents and Hematology- Oncology Fellows. 2003, 2005, 2008

Lecturer: *Laboratory Coagulation: A series of 5 lectures*. Lectures describing basic aspects of Coagulation and hemostasis with emphasis on the principles of laboratory testing : intended for Clinical Pathology residents and Hematology- Oncology Fellows : 2011, 2013

Lecturer: *Applied Transfusion Medicine: A series of 5 lectures*. Lectures presenting clinical problems in Transfusion Medicine as a basis for teaching basic Transfusion Medicine. intended for Clinical Pathology residents and Hematology- Oncology Fellows: 2012, 2014

University of Rhode Island:

Lecturer: Basic Coagulation. Masters Degree candidates. 3 – 6 contact hours. 1996, 1999, 2002, 2004, and 2010